Beneficial effects of fetal–maternal microchimerism on the activated haplo-identical peripheral blood stem cell treatment for cancer

The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-α mediated cellular immunity

“…and some non-immune cells (such as vascular endothelial cells, epidermal cells, fibroblasts, etc.). As a kind of molecule for cell signal transduction, cytokines mainly regulate immune response, participate in immune cell differentiation and development, mediate inflammatory response and stimulate the hematopoietic function and tissue repair [26].…”

Fetal Microchimerism and Cancer

“…Using HLA markers, the fetal or maternal (maternal cells in children) microchimerism status (+ or -) of patients was determined prior to treatment with the haplo-PBSC derived from the donor. Both the survival time and therapeutic response rate of microchimerism-positive patients was higher than in microchimerism-negative patients (8). In yet another study, the percentage of parous patients with malignancies that were positive for fetal microchimeric cells was significantly less than for normal parous donors (9).…”

Microchimérisme fœtal : un bien ou un mal pour le fœtus et sa mère ?

“…La probabilité d'avoir un cancer serait moindre chez les femmes multipares avec microchimé risme que chez celles sans microchimé risme [92]. Le MCF serait moins fré quent dans le sang pé riphé rique de femmes pré sentant certains types de cancer [14,93,94].…”